Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 473159, 10 pages
http://dx.doi.org/10.1155/2015/473159
Research Article

Full GMP-Compliant Validation of Bone Marrow-Derived Human CD133+ Cells as Advanced Therapy Medicinal Product for Refractory Ischemic Cardiomyopathy

1Laboratory of Cell Therapy “Stefano Verri”, Azienda Ospedaliera San Gerardo, Via Pergolesi 33, 20900 Monza, Italy
2Department of Health Science, Università degli Studi di Milano-Bicocca, piazza dell’Ateneo Nuovo 1, 20126 Milan, Italy
3Tettamanti Research Center, Azienda Ospedaliera San Gerardo, Via Pergolesi 33, 20900 Monza, Italy
4Laboratory of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino, IRCCS, Via Parea 4, 20138 Milan, Italy
5Department of Pediatrics, MBBM Foundation, Ospedale San Gerardo, Via Pergolesi 33, 20900 Monza, Italy
6Department of Ematology, Azienda Ospedaliera San Gerardo, Via Pergolesi 33, 20900 Monza, Italy
7Department of Cardiovascular Surgery, Centro Cardiologico Monzino, IRCCS, Via Parea 4, 20138 Milan, Italy
8Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Via Festa del Perdono 7, 20122 Milan, Italy

Received 19 March 2015; Accepted 11 May 2015

Academic Editor: Sebastiano Sciarretta

Copyright © 2015 Daniela Belotti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Colombo, M. Castellani, E. Piccaluga et al., “Myocardial blood flow and infarct size after CD133+ cell injection in large myocardial infarction with good recanalization and poor reperfusion: results from a randomized controlled trial,” Journal of Cardiovascular Medicine, vol. 12, no. 4, pp. 239–248, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Mansour, D.-C. Roy, V. Bouchard et al., “One-year safety analysis of the COMPARE-AMI trial: comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction,” Bone Marrow Research, vol. 2011, Article ID 385124, 6 pages, 2011. View at Publisher · View at Google Scholar
  3. B. A. Nasseri, W. Ebell, M. Dandel et al., “Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: the Cardio133 trial,” European Heart Journal, vol. 35, no. 19, pp. 1263–1274, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Stamm, H.-D. Kleine, Y.-H. Choi et al., “Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies,” The Journal of Thoracic and Cardiovascular Surgery, vol. 133, no. 3, pp. 717–725, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Mansour, D.-C. Roy, V. Bouchard et al., “COMPARE-AMI trial: comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction: study rationale and design,” Journal of Cardiovascular Translational Research, vol. 3, no. 2, pp. 153–159, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Bartunek, M. Vanderheyden, B. Vandekerckhove et al., “Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety,” Circulation, vol. 112, no. 9, pp. I178–I183, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. U. Kurbonov, A. Dustov, A. Barotov et al., “Intracoronary infusion of autologous CD133+ cells in myocardial infarction and tracing by Tc99m MIBI scintigraphy of the heart areas involved in cell homing,” Stem Cells International, vol. 2013, Article ID 582527, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Manginas, E. Goussetis, M. Koutelou et al., “Pilot study to evaluate the safety and feasibility of intracoronary CD133+ and CD133 CD34+ cell therapy in patients with nonviable anterior myocardial infarction,” Catheterization and Cardiovascular Interventions, vol. 69, no. 6, pp. 773–781, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Babin-Ebell, H.-H. Sievers, E. I. Charitos et al., “Transmyocardial laser revascularization combined with intramyocardial endothelial progenitor cell transplantation in patients with intractable ischemic heart disease ineligible for conventional revascularization: preliminary results in a highly selected small patient cohort,” The Thoracic and Cardiovascular Surgeon, vol. 58, no. 1, pp. 11–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. H. M. Klein, A. Ghodsizad, R. Marktanner et al., “Intramyocardial implantation of CD133+ stem cells improved cardiac function without bypass surgery,” The Heart Surgery Forum, vol. 10, no. 1, pp. E66–E69, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. D. S. Adler, H. Lazarus, R. Nair et al., “Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy,” Frontiers in Bioscience, vol. 3, no. 2, pp. 506–514, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Stamm, B. Westphal, H. D. Kleine et al., “Autologous bone-marrow stem-cell transplantation for myocardial regeneration,” The Lancet, vol. 361, no. 9351, pp. 45–46, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Stamm, H.-D. Kleine, B. Westphal et al., “CABG and bone marrow stem cell transplantation after myocardial infarction,” The Thoracic and Cardiovascular Surgeon, vol. 52, no. 3, pp. 152–158, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Bongiovanni, B. Bassetti, E. Gambini et al., “he CD133+ cell as advanced medicinal product for myocardial and limb ischemia,” Stem Cells and Development, vol. 23, no. 20, pp. 2403–2421, 2014. View at Publisher · View at Google Scholar
  15. N. Quirici, D. Soligo, L. Caneva, F. Servida, P. Bossolasco, and G. L. Deliliers, “Differentiation and expansion of endothelial cells from human bone marrow CD133+ cells,” British Journal of Haematology, vol. 115, no. 1, pp. 186–194, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Peichev, A. J. Naiyer, D. Pereira et al., “Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors,” Blood, vol. 95, no. 3, pp. 952–958, 2000. View at Google Scholar
  17. A. A. Kocher, M. D. Schuster, M. J. Szabolcs et al., “Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function,” Nature Medicine, vol. 7, no. 4, pp. 430–436, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Urbich, A. Aicher, C. Heeschen et al., “Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells,” Journal of Molecular and Cellular Cardiology, vol. 39, no. 5, pp. 733–742, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. U. Koehl, S. Zimmermann, R. Esser et al., “Autologous transplantation of CD133 selected hematopoietic progenitor cells in a pediatric patient with relapsed leukemia,” Bone Marrow Transplantation, vol. 29, no. 11, pp. 927–930, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Jimenez-Quevedo, J. J. Gonzalez-Ferrer, M. Sabate et al., “Selected CD133+ progenitor cells to promote angiogenesis in patients with refractory angina: final results of the PROGENITOR randomized trial. Circulation research,” Circulation Research, vol. 115, no. 11, pp. 950–960, 2014. View at Publisher · View at Google Scholar
  21. Guideline on Human Cell-Based Medicinal Products (EMEA/CHMP/410869/2006), 2008.
  22. Reflection Paper on Stem Cell-Based Medicinal Products. EMA/CAT/571134/2009, 2011.
  23. EU Legislation—Eudralex—European Commission. Volume 4—Guidelines for good manufacturing practices for medicinal products for human and veterinary use.
  24. E. C. Perin, J. T. Willerson, C. J. Pepine et al., “Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial,” Journal of the American Medical Association, vol. 307, no. 16, pp. 1717–1726, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Dimmeler and A. Leri, “Aging and disease as modifiers of efficacy of cell therapy,” Circulation Research, vol. 102, no. 11, pp. 1319–1330, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Gaipa, M. Tilenni, S. Straino et al., “GMP-based CD133+ cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy,” Journal of Cellular and Molecular Medicine, vol. 14, no. 6, pp. 1619–1634, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. https://clinicaltrials.gov/ct2/show/NCT02059681.
  28. ICH, “ICH harmonised tripartite guideline Q9: quality risk management,” in Proceedings of the International Conference on Harmonisation (ICH '06), 2006.
  29. European Commission, “The rules governing medicinal products in the European Union, medicinal products for human and veterinary use,” Annex 13 ENTR/F/2/AM/an D(2010) 3374, European Commission, Brussels, Belgium, 2010. View at Google Scholar
  30. R. Nims, E. Presente, G. Sofer, C. Phillips, and A. Chang, “Adventitious agents: concerns and testing for biopharmaceuticals,” in Process Validation in Manufacturing of Biopharmaceuticals: Guidelines, Current Practices, and Industrial Case Studies, A. S. Rathore and G. Sofer, Eds., pp. 143–167, CRC Press/Informa, Boca Raton, Fla, USA, 2005. View at Google Scholar
  31. Scientific Recommendation on Classification of Advanced Therapy Medicinal Products. EMA/921674/2011, 2011.
  32. G. Pompilio, M. C. Capogrossi, M. Pesce et al., “Endothelial progenitor cells and cardiovascular homeostasis: clinical implications,” International Journal of Cardiology, vol. 131, no. 2, pp. 156–167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Pompilio, G. Steinhoff, A. Liebold et al., “Direct minimally invasive intramyocardial injection of bone marrow-derived AC133+ stem cells in patients with refractory ischemia: preliminary results,” The Thoracic and Cardiovascular Surgeon, vol. 56, no. 2, pp. 71–76, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. G. P. Fadini, D. Losordo, and S. Dimmeler, “Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use,” Circulation Research, vol. 110, no. 4, pp. 624–637, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Flores-Ramírez, A. Uribe-Longoria, M. M. Rangel-Fuentes et al., “Intracoronary infusion of CD133+ endothelial progenitor cells improves heart function and quality of life in patients with chronic post-infarct heart insufficiency,” Cardiovascular Revascularization Medicine, vol. 11, no. 2, pp. 72–78, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Schots, G. de Keulenaer, D. Schoors et al., “Evidence that intracoronary-injected CD133+ peripheral blood progenitor cells home to the myocardium in chronic postinfarction heart failure,” Experimental Hematology, vol. 35, no. 12, pp. 1884–1890, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. D. W. Losordo, T. D. Henry, C. Davidson et al., “Intramyocardial, autologous CD34+ cell therapy for refractory angina,” Circulation Research, vol. 109, no. 4, pp. 428–436, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Ahmadi, M. M. Farahani, A. Kouhkan et al., “Five-Year follow-up of the local autologous transplantation of CD133+ enriched bone marrow cells in patients with myocardial infarction,” Archives of Iranian Medicine, vol. 15, no. 1, pp. 32–35, 2012. View at Google Scholar · View at Scopus